These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 18578973

  • 1. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
    Toussirot E, Pertuiset E, Kantelip B, Wendling D.
    Clin Exp Rheumatol; 2008; 26(3):471-5. PubMed ID: 18578973
    [Abstract] [Full Text] [Related]

  • 2. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
    Toussirot E, Berthelot JM, Pertuiset E, Bouvard B, Gaudin P, Wendling D, le Noach J, Lohse A, Lecuyer E, Cri L.
    J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
    [Abstract] [Full Text] [Related]

  • 3. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
    Clementine RR, Lyman J, Zakem J, Mallepalli J, Lindsey S, Quinet R.
    J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
    [Abstract] [Full Text] [Related]

  • 4. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.
    Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J, Club Rhumatismes et Inflammation (CRI).
    Rheumatology (Oxford); 2009 Aug; 48(8):883-6. PubMed ID: 19423648
    [Abstract] [Full Text] [Related]

  • 5. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, Berthelot JM, Bader-Meunier B, Kantelip B, Le CRI.
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [Abstract] [Full Text] [Related]

  • 6. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication.
    Tong D, Manolios N, Howe G, Spencer D.
    Intern Med J; 2012 Jan; 42(1):89-94. PubMed ID: 22389903
    [Abstract] [Full Text] [Related]

  • 7. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 8. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D, Braunstahl GJ, van Zeben J, Wouters J.
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR.
    Arthritis Res; 2002 Dec; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [Abstract] [Full Text] [Related]

  • 12. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.
    Clin Exp Rheumatol; 2012 Dec; 30(1):31-8. PubMed ID: 22153557
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 15. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May 18; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 16. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C.
    Acta Reumatol Port; 2007 May 18; 32(2):139-50. PubMed ID: 17572652
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.
    Ann Rheum Dis; 2008 May 18; 67(5):710-2. PubMed ID: 18079191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.